Claims
- 1. An isolated, vertebrate nucleic acid molecule of bcl-6 locus.
- 2. A DNA molecule of claim 1.
- 3. A cDNA molecule of claim 2.
- 4. A genomic DNA molecule of claim 2.
- 5. An RNA molecule of claim 1.
- 6. A human nucleic acid molecule of claim 1.
- 7. A nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the nucleic acid molecule of the bcl-6 locus.
- 8. A DNA molecule of claim 7.
- 9. An RNA molecule of claim 7.
- 10. An isolated, vertebrate nucleic acid molecule of claim 3 operatively linked to a promoter of RNA transcription.
- 11. A vector which comprises the nucleic acid molecule of claims 2 or 10.
- 12. A vector of claim 11, wherein the isolated nucleic acid molecule is linked to a plasmid.
- 13. The nucleic acid molecule of claim 12 designated pGB31 (ATCC Accession No. 75476).
- 14. The nucleic acid molecule of claim 12 designated pGB3s (ATCC Accession No. 75477).
- 15. A host vector system for the production of a polypeptide encoded by bcl-6 locus, which comprises the vector of claim 11 in a suitable host.
- 16. A host vector system of claim 15, wherein the suitable host is a bacterial cell, insect cell, or animal cell.
- 17. A method of producing a polypeptide encoded by bcl-6 locus, which comprises growing the host vector system of claim 11 under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.
- 18. A polypeptide encoded by the isolated, vertebrate nucleic acid molecule of claim 1.
- 19. An antibody capable of binding to polypeptide encoded by bcl-6.
- 20. A monoclonal antibody of claim 19.
- 21. A polyclonal antibody of claim 19.
- 22. The isolated nucleic acid molecule of claim 1 that is labelled with a detectable marker.
- 23. The isolated nucleic acid molecule of claim 22, wherein the marker is a radioactive label, a calorimetric, luminescent, or a fluorescent marker.
- 24. An antagonist capable of blocking the expression of claim 18.
- 25. The antagonist of claim 24, wherein the antagonist is a triplex oligonucleotide capable of hybridizing to nucleic acid molecule of claim 1.
- 26. An antisense molecule capable of hybridizing to the nucleic acid molecule of claim 1.
- 27. The antisense molecule of claim 26, wherein the molecule is a DNA.
- 28. The antisense molecule of claim 26, wherein the molecule is a RNA.
- 29. A triplex oligonucleotide capable of hybridizing with a double stranded DNA molecule of claim 2.
- 30. A transgenic nonhuman mammal which comprises the isolated nucleic acid molecule of claim 1 introduced into the mammal at an embryonic stage.
- 31. An assay for non-Hodgkin's lymphoma, comprising (a) incubating a sample of suitable body fluid for a subject with a monoclonal antibody reactive with non-Hodgkin's lymphoma cells to a solid support, (b) removing unbound body fluid from the support, and (c) determining the level of antigen activity exhibited by the bound body fluid to the support.
- 32. A method for screening putative therapeutic agents for treatment of non-Hodgkin's lymphoma, which comprises determining in a first sample from a subject with non-Hodgkin's lymphoma the presence of the isolated nucleic acid molecule of claim 1, administering to the subject a therapeutic amount of the agent such that the agent is contacted with the cell associated with the condition, determining after a suitable period the amount of the isolated nucleic acid molecule in a sample from the treated subject, and comparing the amount of isolated nucleic acid molecule determined in the first sample with the amount determined in the sample from the treated subject, a difference indicating the effectiveness of the agent, thereby screening putative therapeutic agents for treatment of non-Hodgkin's lymphoma.
- 33. A method for diagnosing B-cell lymphoma in a subject comprising:
(a) obtaining DNA sample from the subject; (b) cleave the DNA sample into fragments; (c) separating the DNA fragments by size fractionation; (d) hybridizing the DNA fragments with a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the nucleic acid molecule of the bcl-6 locus to detect the DNA fragment containing the bcl-6 sequence; and (e) comparing the detected DNA fragment from (d) with the DNA fragment from a known normal subject, the difference in size of the fragments indicating the occurrence of B-cell lymphoma in the subject.
- 34. A method of claim 33, where in step (b), the DNA sample is cleaved by restriction enzyme.
- 35. A method of claim 33, wherein the size fractionation is step (c) is effected by a polyacrylamide or agarose gel.
- 36. A method of claim 33, where in step (d), the nucleic acid molecule is labeled with a detectable marker.
- 37. A method of claim 36, wherein the detectable marker is a radiolabelled molecule, a fluorescent molecule, an enzyme, or a ligand.
- 38. A method of claim 33, further comprising transferring the DNA fragments into a solid matrix before step (d).
- 39. A method for diagnosing B-cell lymphoma in a subject comprising:
(a) obtaining RNA sample from the subject; (b) separating the RNA sample into different species by size fractionation; (c) hybridizing the RNA species with a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the nucleic acid molecule of the bcl-6 locus to detect the RNA species containing the bcl-6 sequence; and (d) comparing the detected RNA species from step (c) with the RNA species from a known normal subject, the difference in size of the species indicating the occurrence of B-cell lymphoma in the subject.
- 40. A method of claim 39, wherein the size fractionation in step (b) is effected by a polyacrylamide or agarose gel.
- 41. A method of claim 39, where in step (c), the nucleic acid molecule is labeled with a detectable marker.
- 42. A method of claim 41, wherein the detectable marker is a radiolabelled molecule, a fluorescent molecule, an enzyme, or a ligand.
- 43. A method of claim 39, further comprising transferring the RNA species into a solid matrix before step (c).
- 44. A method of treating a subject with non-Hodgkin's lymphoma, comprising administering an effective amount of the antisense molecule of claim 26 operatively linked to a suitable regulatory element coupled with a therapeutic DNA into a tumor cell of a subject, thereby treating the subject with non-Hodgkin's lymphoma.
- 45. A method of treating a subject with non-Hodgkin's lymphoma, comprising administering an effective amount of the antagonist of claim 23, and a suitable acceptable carrier, thereby treating the subject with non-Hodgkin's lymphoma.
Parent Case Info
[0001] This application is a continuation-in-part of United States application Ser. No. 08/074,967, filed on Jun. 9, 1993, the contents of which are hereby incorporated by reference.
Government Interests
[0002] The invention disclosed herein was made with Government support under NIH Grant Nos. CA-44029, CA-34775, CA-08748 and CA-37295 from the Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09268202 |
Mar 1999 |
US |
Child |
09761117 |
Jan 2001 |
US |
Parent |
08553541 |
May 1996 |
US |
Child |
09268202 |
Mar 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US94/06669 |
Jun 1994 |
US |
Child |
08553541 |
May 1996 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08074967 |
Jun 1993 |
US |
Child |
PCT/US94/06669 |
Jun 1994 |
US |